I am working on designing immunomodulatory antibody therapies, including T-cell agonists, T-cell engagers, and immunocytokines. These molecules have shown promise for treating a number of diseases, including cancer and autoimmunity.

Co-advised by Prof. Peter Tessier

Exploration of Krogh cylinder model refinement with payload recycling.

The recent successes of ADCs in the clinic have underscored the importance of tailoring ADC drug properties for specific targets. However, the complexity of these molecules poses a challenge in thoroughly screening all potential combinations of protein, linker, and payload during development. My work focuses on applying fundamental drug transport principles to efficiently design ADCs for maximum efficacy at clinically tolerated doses.

Modeling drug uptake and distribution across the BBB (Blood-Brain Barrier) to enable the testing of hypotheses for applications such as treating neurodegenerative diseases (e.g., Alzheimer’s and MS) and cancer. 

Co-advised by Prof. Peter Tessier

Developing specialized ADCs with Fc-engineered domain to maximize immune response and drive lasting tumor remission.

Designing 1×1 bispecific antibody shuttles to facilitate the transport of biomolecules across the blood-brain barrier for the treatment of neurological diseases.

Co-advised by Prof. Peter Tessier

Engineering Antibody-Based Therapeutics Against Solid Tumors

Immune cell characterization after treatment with novel antibody-drug conjugates (ADCs) and immune stimulating drugs in oncology

Understanding the interactions between cancer therapeutics and the tumor micro-environment. Combining agent-based modeling to investigate immune checkpoint inhibitor activity and T-cell dynamics, alongside in vivo models to study the distribution of cross-reactive antibody-drug conjugates

Developing novel models for studying ADC and immuno-oncology therapeutics

Computer programming support for multi-scale models